Submission of clinical trial notification for RPE tear using RPE cells derived from allogeneic iPS cells (HLCR011)
(Published: May 25,2023)

Sumitomo Pharma Co., Ltd. and HEALIOS K.K. announced on May 25, 2023 that Sumitomo Pharma has submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) a clinical trial notification for a phase 1/2 study in patients with retinal pigment epithelium (RPE) tear regarding a treatment using retinal pigment epithelial (RPE) cells (development code: HLCR011) derived from allogeneic iPS cells which is being co-developed in Japan. This clinical trial is scheduled to start after a 30-day review period.

Restore Vision Closes Series A Round Funding Aims to Begin First-in-Human Study in 2024 (Published: June 5, 2023)

Restore Vision Inc., a biopharmaceutical company in Japan aiming to fast-track the development of a treatment to restore vision through gene therapy, announced today that it has successfully secured a 1.3 billion JPY Series A round funding (“Funding”) with the lead investor Remiges Ventures and existing investors ANRI and Real Tech Fund, and with new investors DBJ Capital, QB Capital, SMBC Venture Capital, Spiral Capital, and Higin Capital. The company is expecting to raise additional funds with new investors in connection with this Funding as well.